Tenax Therapeutics Inc (TENX) Actualités

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board

CHAPEL HILL, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)FDA agreement that...